Abstract:Abstract This abstract discusses an unusual rash caused by an atypical infection in a susceptible individual. A 52-year-old patient was referred in 2022 with a 12-month history of a progressive rash on the right leg with tender, inflamed and erythematous lesions. The patient had a background of severe relapsing polychondritis that was diagnosed in 2016. The disease was being managed with prednisolone 30 mg once daily, after previous failure of other immunosuppressive agents including methotrexate, azathioprine and 6 cycles of IV cyclophosphamide. Additionally, the patient was also on co-trimoxazole for Pneumocystis jirovecii pneumonia prophylaxis. On examination, erythematous and violaceous plaques and nodules were noted at the right leg with the lesions clustering and coalescing at the right medial thigh. A few of the lesions appeared infiltrated with pale material. Several warts were noted on the dorsal aspect of the hands, indicating significant immunosuppression. Differential diagnoses considered included the following: a vasculitic process, deposition disorders or an infective process. An urgent biopsy revealed palisaded granulomatous and neutrophilic dermatosis, indicative of an infectious aetiology. The patient was referred to the infectious diseases team. Acid alcohol-fast bacteria culture and whole-genome sequencing revealed a diagnosis of Mycobacteroides chelonae, a nontuberculous mycobacterium. The patient was commenced on 6 months’ treatment with combined doxycycline 100 mg twice daily and clarithromycin 500 mg twice daily. The patient responded well to treatment, with resolution of nodules on treatment completion. This case highlights the need for an increased index of suspicion in patients with a history of significant immunosuppression. Our patient had undergone QuantiFERON Gold (negative) in 2020 prior to IV cyclophosphamide. There is some evidence to suggest that QuantiFERON Gold may have the capacity to identify patients with nontuberculous mycobacteria (Kobashi Y, Mouri K, Yagi S et al. Clinical evaluation of the QuantiFERON-TB Gold test in patients with non-tuberculous mycobacterial disease. Int J Tuberc Lung Dis 2009; 13: 1422–6). There is robust guidance on TB infection screening prior to initiating immunosuppression (interferon-γ release assay and chest radiograph) [National Institute for Health and Care Excellence. Scenario: monitoring of DMARDs. Available at https://cks.nice.org.uk/topics/dmards/management/monitoring-of-dmards/ (last accessed 24 March 2024)]. However, there is a relative paucity of guidance related to infection monitoring after commencement of immunosuppression and the need for repeat QuantiFERON testing. Given the increasing use of complex chemotherapy and immunosuppression regimens in standard practice, retaining a high index of suspicion for complex or atypical infection remains important and serves to highlight the need for appropriate investigation. Developing appropriate guidelines to rationalize infection monitoring of patients on long-term immunosuppression could further improve patient care.

Experience of dermatologic biologic therapy use and associated opportunistic infection management in Australia's tropical north

The Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australia

Transition of pediatric patients with bronchiectasis to adult medical care in the Northern Territory: A retrospective chart audit

Bronchiectasis among Indigenous adults in the Top End of the Northern Territory, 2011–2020: a retrospective cohort study

Factors leading to diagnostic delay in tuberculosis in the tropical north of Australia

Is tropical pus in the hand special? A retrospective study comparing hand infection cases in Darwin and Adelaide

Malignant otitis externa in Australian Aboriginal patients: A 9-year retrospective analysis from the Northern Territory

P031 Experience from a UK dermatology regional virtual biologics and high-cost drugs multidisciplinary team

Skin health of Aboriginal children living in urban communities

BI35 A 12-month history of a progressive rash on a background of significant long-term immunosuppression

Health issues of refugees attending an infectious disease refugee health clinic in a regional Australian hospital

Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study

IDDF2018-ABS-0061 Risk of Tuberculosis in Inflammatory Bowel Disease and Other Immune-Mediated Diseases on Biological Therapy: a Population-Based Study in Hong Kong

Antiphospholipid syndrome in rural, remote, and First Nations peoples in the Top End of the Northern Territory, Australia

Risk of Tuberculosis in Patients with Immune-Mediated Diseases on Biological Therapies: a Population-Based Study in a Tuberculosis Endemic Region

Tele-otology for Aboriginal and Torres Strait Islander People Living in Rural and Remote Areas

TB treatment using family members, treatment supporters and self-administered therapies in rural Papua New Guinea

Investigating cutaneous tuberculosis and nontuberculous mycobacterial infections a Department of Dermatology, Beijing, China: a comprehensive clinicopathological analysis

Community treatment of latent tuberculosis in child and adult refugee populations: outcomes and successes

Dialysis attendance patterns and health care utilisation of Aboriginal patients attending dialysis services in urban, rural and remote locations

Loss to follow-up among adults with drug-resistant TB in Papua New Guinea